Eric is focused on identifying disruptive technologies that have the potential to open new frontiers in healthcare. With an emphasis on drug development and medical technologies, he works closely with entrepreneurs to build companies whose mission is to advance the practice of medicine and promote human health.
Prior to joining DCVC Bio, Eric was a Partner at Novo Ventures where he established and managed the firm’s public equities strategy focused on SMID-Cap and late-stage private companies in biotech and medtech. Earlier in his career, Eric was a Director at Apposite Capital and an Associate at Burrill & Company. Having initially trained as a structural biologist, he served as a Leukemia & Lymphoma Society Post-Doctoral Fellow. Eric received a bachelor’s degree in biophysics from Johns Hopkins University and a PhD in molecular biology from Princeton University.
